Collaborative Networks Driving Regulatory Transformation in Latin America
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
IVAX Argentina, member of the Teva Group, is one of the leading companies in the local pharmaceutical industry, Teva. Permanent growth is driven by more than 46,000 employees in 60 countries.
In Argentina, IVAX offers products and services of excellence for healthcare and improving the quality of life of human beings.
Our products are designed to treat a wide range of pathologies, highlighting the cardiometabolic, neurological and psychiatric, osteoarticular and muscular system, oncology, HIV, onco-urological diseases, gastroenterological and hepatológicas. The Company offers a line of women’s health for different indications.
Among the main products COPAXONE is leading the world market (Glatiramer Acetate) for the treatment of Multiple Sclerosis. Committed to the quality of life of patients, the company has a program of care for patients with Multiple Sclerosis: Shared Solutions, designed to provide information and control to all patients treated with Copaxone.
The company produces and sells about 120 drug products in more than 250 trade shows.
Address: Juan José Castelli 6701 – B1652ACM – Villa Adelina – Province of Buenos Aires – Argentina
Patients and health professionals:
0800-666-3342 info@ivax.com.ar
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
Axios International has been designing and implementing access to healthcare solutions in collaboration with the pharmaceutical industry and other healthcare players across Latin America (LatAm), Europe, the Middle East, Africa,…
Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth…
See our Cookie Privacy Policy Here
